Unlock stock picks and a broker-level newsfeed that powers Wall Street.
0.0001
0.0000
(0.00%)
At close: March 11 at 4:00:00 PM EDT
Breakdown
TTM
Total Revenue
265.4660
Cost of Revenue
91.4990
Gross Profit
173.9670
Operating Expense
1,341.3460
Operating Income
-1,167.3790
Net Non Operating Interest Income Expense
-83.5120
Other Income Expense
-144.8910
Pretax Income
-1,395.7820
Net Income Common Stockholders
-1,395.7820
Diluted NI Available to Com Stockholders
-1,395.7820
Basic EPS
-0.05
Diluted EPS
-0.05
Basic Average Shares
28,136.5270
Diluted Average Shares
28,136.5270
Total Operating Income as Reported
-1,310.3480
Total Expenses
1,432.8450
Net Income from Continuing & Discontinued Operation
-1,395.7820
Normalized Income
-1,257.5210
Interest Expense
83.5120
Net Interest Income
-83.5120
EBIT
-1,312.2700
EBITDA
-1,294.5730
Reconciled Cost of Revenue
91.4990
Reconciled Depreciation
17.6970
Net Income from Continuing Operation Net Minority Interest
-1,395.7820
Total Unusual Items Excluding Goodwill
-138.2610
Total Unusual Items
-138.2610
Normalized EBITDA
-1,156.3120
-
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
SYBX Synlogic, Inc.
1.2300
-2.38%
CALC CalciMedica, Inc.
2.0700
-4.61%
CARA Cara Therapeutics, Inc.
5.13
+4.38%
CCCC C4 Therapeutics, Inc.
2.0500
-5.09%
ADAP Adaptimmune Therapeutics plc
0.4470
-0.69%
BIVI BioVie Inc.
1.0450
-4.13%
NUVB Nuvation Bio Inc.
2.2900
+21.81%
FATE Fate Therapeutics, Inc.
0.9599
+3.57%
VRTX Vertex Pharmaceuticals Incorporated
488.34
-2.33%